Neonode Second Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.098 loss in 2Q 2023)

August 14, 2024

Simply Wall St

Neonode (NASDAQ:NEON) Second Quarter 2024 Results

Key Financial Results

Revenue: US$1.42m (up 19% from 2Q 2023).
Net loss: US$1.70m (loss widened by 13% from 2Q 2023).
US$0.11 loss per share (further deteriorated from US$0.098 loss in 2Q 2023).

earnings-and-revenue-growth — NasdaqCM:NEON Earnings and Revenue Growth August 14th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Neonode Earnings Insights

Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Electronic industry in the US.

Performance of the American Electronic industry.

The company's shares are down 1.9% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Neonode (1 is potentially serious!) that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Neonode might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

mitchell_lawler

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

128

pri_dlp7z4h

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.

Quantanium3h

There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.

Market might be getting a little ahead of itself here.

About NasdaqCM:NEON

Neonode

Provides software solutions for machine perception to detect and track persons and objects in video streams from cameras and other types of imagers in the United States, Japan, South Korea, Germany, Sweden, China, and internationally.

See The Free Research Report